Curia Global - Leading Global CDMO Curia is a global CDMO with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing We offer services across Small Molecules, Generic APIs, and Biologics backed by deep scientific expertise and a robust global network of resources and capabilities
Curia Announces Strategic Refinancing to Support Continued Growth Albany, New York, Mar 7, 2025 — Curia Global, Inc (Curia), a leading contract research, development and manufacturing organization, today announced it has refinanced its senior secured credit facilities
About Us | Curia Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact
Curia Announces Expansions to Global Network of Sterile Fill-Finish . . . Albany, NY- March 17, 2025 – Curia Global, Inc (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM
Curia Completes Acquisition of LakePharma | Curia - Curia Global With the addition of LakePharma, Curia offers deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production
Curia Global, Inc. 供应商指南 “Curia”)前身为 AMRI,是一家领先的合同研究、开发 和制造组织,为制药和生物制药客户提供从研发到商业制造的产品和服务。 Curia 在美国、
Strategic Government Partnerships | Curia - Curia Global For more than 30 years Curia has successfully partnered with biotech and pharmaceutical companies, government agencies and therapeutic-specific institutes to drive the discovery and development of new medicines
Curia Expands Cell Line Development Offering with CHOZN Platform Curia’s protein and antibody development experts offer a track record of accelerating progress, with a timeline in as little as 12 months from cell line development to phase I drug substance, depending on the manufacturability of the candidates
Molecular Biology | Curia Curia’s Biologics Discovery and Development Capabilities Curia is able to collaborate and partner with you to move your molecule down the pipeline